Texas Yale Capital Corp’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Texas Yale Capital Corp’s Portfolio LOGC Stock Details LOGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-20,000	Closed	-$5K	–	481
2022 Q3	$5K	Hold	20,000	–	–	﹤0.01%	452
2022 Q2	$7K	Hold	20,000	–	–	﹤0.01%	449
2022 Q1	$14K	Hold	20,000	–	–	﹤0.01%	466
2021 Q4	$46K	Hold	20,000	–	–	﹤0.01%	467
2021 Q3	$92K	Hold	20,000	–	–	0.01%	455
2021 Q2	$89K	Buy	20,000 +10,000	+100%	+$50.9K	0.01%	456
2021 Q1	$73K	Buy	+10,000	New	+$82.3K	﹤0.01%	437

Texas Yale Capital Corp's LOGC Position: Q4 2022 in Review

Texas Yale Capital Corp sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q4 2022, closing a stake of 20,000 shares — an estimated $5K sold.

Texas Yale Capital Corp first reported a position in LOGC in Q1 2021 and held it in 7 quarters. The position peaked at $92K in Q3 2021. 0 funds tracked by Wall St. Rank hold LOGC as of Q4 2022.

Texas Yale Capital Corp reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Texas Yale Capital Corp sold 20,000 LogicBio Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $5K.
Texas Yale Capital Corp first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q1 2021 and held it in 7 quarters.
Texas Yale Capital Corp's LogicBio Therapeutics, Inc. Common Stock position peaked at $92K in Q3 2021.
0 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Texas Yale Capital Corp's 13F filing for Q4 2022, filed 13 Feb 2023.